Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate-Lung01
jRCT2041220019Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, randomised, open-label trial of ifinatamab deruxtecan in small cell lung cancer (SCLC) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective response rate by blinded independent central review. Started Jul 2022; status: active, not recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2041220019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220019.